Amgen Inc. (NASDAQ:AMGN) Shares Sold by West Oak Capital LLC

West Oak Capital LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 8,477 shares of the medical research company’s stock after selling 255 shares during the quarter. Amgen comprises approximately 1.2% of West Oak Capital LLC’s portfolio, making the stock its 21st largest holding. West Oak Capital LLC’s holdings in Amgen were worth $2,598,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Roundview Capital LLC boosted its stake in Amgen by 1.3% during the 1st quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock valued at $2,027,000 after acquiring an additional 107 shares during the last quarter. Merit Financial Group LLC lifted its holdings in shares of Amgen by 39.2% in the 1st quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock worth $555,000 after purchasing an additional 647 shares during the last quarter. Ergoteles LLC acquired a new position in shares of Amgen during the first quarter valued at $219,000. First Western Trust Bank acquired a new position in shares of Amgen during the first quarter valued at $334,000. Finally, Fuller & Thaler Asset Management Inc. grew its position in Amgen by 2.1% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after buying an additional 513 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.0 %

Shares of AMGN stock traded down $0.13 on Thursday, reaching $286.17. 445,657 shares of the company’s stock traded hands, compared to its average volume of 3,009,910. The company has a market capitalization of $153.36 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 2.66 and a beta of 0.58. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The business’s 50 day moving average price is $290.44 and its two-hundred day moving average price is $280.66.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.09 EPS. On average, equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.14%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMGN. Royal Bank of Canada upped their price target on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. UBS Group decreased their target price on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.